7 June 2020 - Imperial College aims to develop a vaccine that is cheaper and easier to manufacture and is forming a partnership to sell it in low-income countries and Britain.

A prominent British laboratory is forming a special partnership that would sidestep the drug industry to sell a potential vaccine against the coronavirus without profits or licensing fees in Britain and in low- and middle-income countries.

Scientists, non-profit groups and public health experts have urged that any successful vaccine to combat the pandemic be distributed at the lowest possible cost and on the basis of need rather than profit. But for-profit drug giants or biotechnology start-ups have dominated the development race, especially in the United States, a vital market because of its high drug prices.

Read New York Times article